Dexcom (DXCM) Q4 2022 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2022 earnings summary
4 Nov, 2026Executive summary
Revenue grew 19% to $2.91B in 2022, with annual new-customer additions reaching a record; the year ended with an estimated 1.7M global CGM users.
G7 received CE Mark and FDA clearance, while expansion of Dexcom ONE and proposed Medicare coverage for more people with type 2 diabetes broadened access opportunities.
Financial highlights
Revenue was $2,909.8M, up 19% YoY; gross profit rose 12% to $1,883.1M, while operating income increased 47% to $391.2M.
Net income increased 57% to $341.2M; diluted EPS was $0.82 versus $0.53 in 2021, on an adjusted comparative basis.
Operating cash flow rose 51% to $669.5M; cash, cash equivalents and short-term marketable securities totaled $2.46B at year-end.
Cost of sales rose 34% to $1,026.7M; gross margin fell to 64.7% from 68.6%, primarily due to price, product and channel mix, and FX impacts.
2022 SG&A included a $23.0M noncash impairment charge; 2021 included an $87.1M Verily regulatory milestone R&D charge.
Outlook and guidance
Priorities for 2023 include the continued G7 and Dexcom ONE rollouts, expanding global CGM access, and serving new populations, including U.S. customers with type 2 diabetes on basal insulin.
Manufacturing scale-up is underway for G7; production at the first international facility in Malaysia was expected to begin in 2023.
A CMS coverage proposal for people with type 2 diabetes using basal insulin was slated to take effect in April 2023, potentially broadening access to an estimated 3M U.S. people in that group.
Existing cash, short-term investments and expected operating cash flows were considered sufficient for core operations and anticipated liquidity needs for at least the next 12 months.
Latest events from Dexcom
- Revenue growth and margin gains were offset by lower earnings and a major Verily charge.DXCM
Q4 2021 - Revenue climbed 43% as profitability arrived and G6 capacity doubled.DXCM
Q4 2019 - 31% revenue growth and 66% gross margin, with earnings lifted by a major tax benefit.DXCM
Q4 2020 - G6-led revenue topped $1B as launch investment and the Verily charge widened losses.DXCM
Q4 2018 - Q3 revenue and margins grew, lifting FY2026 guidance and supporting a new $1B buyback.DXCM
Q3 2026 - Q4 revenue grew 26% organically as FDA submissions and G7 integrations advanced.DXCM
Q4 2023 - CONNECT data, expanded coverage, and product innovation set stage for accelerated growth.DXCM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 13%, net income 39%, margins and guidance up, $600M shares repurchased.DXCM
Q2 2026 - Q3 2024 saw 2–3% revenue growth, strong international gains, and a $750M share repurchase.DXCM
Q3 2024